OncoMatch/Clinical Trials/NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Is NCT04924075 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Belzutifan for pheochromocytoma/paraganglioma.
Treatment: Belzutifan — This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Pancreatic Cancer
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: EPAS1 hif-2α related genetic alteration
advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
Required: VHL germline mutation
diagnosis of VHL disease as determined by a germline test locally and/or clinical diagnosis
Disease stage
Required: Stage IV
Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Medical Center ( Site 0110) · Los Angeles, California
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130) · Chicago, Illinois
- Northwestern Medicine Cancer Center - Warrenville ( Site 0134) · Warrenville, Illinois
- University of Iowa ( Site 0104) · Iowa City, Iowa
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108) · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04924075 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require EPAS1?
Yes, EPAS1 hif-2α related genetic alteration is a required biomarker for enrollment.
Does this trial require VHL?
Yes, VHL germline mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages